Not available
Quote | AC Immune SA (NASDAQ:ACIU)
Last: | $2.37 |
---|---|
Change Percent: | -0.84% |
Open: | $2.4 |
Close: | $2.37 |
High: | $2.47 |
Low: | $2.33 |
Volume: | 322,902 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | AC Immune SA (NASDAQ:ACIU)
2024-04-02 16:43:27 ET Gainers: Sight Sciences ( SGHT ) +19% . Zapata Computing Holdings ( ZPTA ) +9% . Cal-Maine Foods ( CALM ) +6% . Vanda Pharmaceuticals ( VNDA ) +5% . iHeartMedia ( IHRT ) +5% . Losers: Ac...
2024-03-14 16:55:37 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts Roche ends AC Immune partnership for Alzheimer’s drugs AC Immune issues updates on Phase 2 studies, cash runway Read the full article on Seekin...
Message Board Posts | AC Immune SA (NASDAQ:ACIU)
Subject | By | Source | When |
---|---|---|---|
WOOHOOOOOO WOOHOOOOOO awesome break out | weedtrader420 | investorshub | 06/27/2023 5:01:28 PM |
WOOHOOOOOO WOOHOOOOOO | weedtrader420 | investorshub | 06/27/2023 2:59:02 PM |
FDA fast track | weedtrader420 | investorshub | 06/27/2023 12:24:08 PM |
$ACIU$ | weedtrader420 | investorshub | 06/27/2023 12:21:23 PM |
ACIOU AND SOMETIMES Y | TheFinalCD | investorshub | 06/27/2023 11:20:28 AM |
News, Short Squeeze, Breakout and More Instantly...
AC Immune SA Company Name:
ACIU Stock Symbol:
NASDAQ Market:
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2 ACI-24.060 for Alzheim...
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer's and P...
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative di...